Safety and Efficacy of Deferasirox (ICL670) in Patients With Iron Overload Resulting From Hereditary Hemochromatosis

Inclusion Criteria: * Age 18 years of age or older * Male or female patients homozygous for the C282Y mutation. * Iron overload as documented by serum ferritin and transferrin saturation * No known allergy or contraindication to the administration of deferasirox * Ability to comply with all study-related procedures, medications, and evaluations * Effective use of birth control measures. Exclusion Criteria: * Iron overload not due to hereditary hemochromatosis * Males with hemoglobin \<13 mg/dL, females with hemoglobin \<12 mg/dL * Desferal treatment within 1 month of the screening visit * Patients currently or previously treated with deferiprone or deferasirox * Significant medical condition interfering with the ability to partake in this study * Presence of a surgical or medical condition that might significantly alter the absorption, distribution, metabolism or excretion of any study drug * Clinical evidence of Active Hepatitis B or C * Positive HIV serology * Pregnant or breast feeding patients * Patients treated with systemic investigational drug within 4 weeks prior or with topical investigational drug within 7 days prior to the screening visit Other protocol-defined inclusion/exclusion criteria may apply.